• Media type: E-Article
  • Title: START NOW: a cognitive behavioral skills training for adolescent girls with conduct or oppositional defiant disorder – a randomized clinical trial
  • Contributor: Stadler, Christina; Freitag, Christine M.; Popma, Arne; Nauta‐Jansen, Lucres; Konrad, Kerstin; Unternaehrer, Eva; Ackermann, Katharina; Bernhard, Anka; Martinelli, Anne; Oldenhof, Helena; Gundlach, Malou; Kohls, Gregor; Prätzlich, Martin; Kieser, Meinhard; Limprecht, Ronald; Raschle, Nora M.; Vriends, Noortje; Trestman, Robert L.; Kirchner, Marietta; Kersten, Linda
  • imprint: Wiley, 2024
  • Published in: Journal of Child Psychology and Psychiatry
  • Language: English
  • DOI: 10.1111/jcpp.13896
  • ISSN: 0021-9630; 1469-7610
  • Keywords: Psychiatry and Mental health ; Developmental and Educational Psychology ; Pediatrics, Perinatology and Child Health
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Background</jats:title><jats:p>Conduct disorder (CD) and oppositional defiant disorder (ODD) both convey a high risk for maladjustment later in life and are understudied in girls. Here, we aimed at confirming the efficacy of START NOW, a cognitive‐behavioral, dialectical behavior therapy‐oriented skills training program aiming to enhance emotion regulation skills, interpersonal and psychosocial adjustment, adapted for female adolescents with CD or ODD.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 127 girls were included in this prospective, cluster randomized, multi‐center, parallel group, quasi‐randomized, controlled phase III trial, which tested the efficacy of START NOW (<jats:italic>n</jats:italic> = 72) compared with standard care (treatment as usual, TAU, <jats:italic>n</jats:italic> = 55). All female adolescents had a clinical diagnosis of CD or ODD, were 15.6 (±1.5) years on average (range: 12–20 years), and were institutionalized in youth welfare institutions. The two primary endpoints were the change in number of CD/ODD symptoms between (1) baseline (T1) and post‐treatment (T3), and (2) between T1 and 12‐week follow‐up (T4).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Both treatment groups showed reduced CD/ODD symptoms at T3 compared with T1 (95% CI: START NOW = −4.87, −2.49; TAU = −4.94, −2.30). There was no significant mean difference in CD/ODD symptom reduction from T1 to T3 between START NOW and TAU (−0.056; 95% CI = −1.860, 1.749; Hedge's <jats:italic>g</jats:italic> = −0.011). However, the START NOW group showed greater mean symptom reduction from T1 to T4 (−2.326; 95% CI = −4.274, −0.378; Hedge's <jats:italic>g</jats:italic> = −0.563). Additionally, secondary endpoint results revealed a reduction in staff reported aggression and parent‐reported irritability at post assessment.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Although START NOW did not result in greater symptom reduction from baseline to post‐treatment compared with TAU, the START NOW group showed greater symptom reduction from baseline to follow‐up with a medium effect size, which indicates a clinically meaningful delayed treatment effect.</jats:p></jats:sec>